No Data
No Data
Hong Kong stocks soar | Hutchmed (China) (00013) rises over 5% again. The company has recently introduced progress in innovative drugs. Institutions say that research and development progress is rapid.
Hutchmed (China) (00013) rose more than 5%, as of publication, up 5.41%, reported at HKD 31.2, with a turnover of HKD 44.2823 million.
China Securities Co.,Ltd: Accelerating development of the self-immunity market to promote the improvement and efficiency of the domestic innovative drug industry.
The patient population with autoimmune diseases and type II inflammation is growing rapidly, the market size is second only to cancer drugs, but still in a period of accelerated development. Existing drugs still have huge room for improvement in efficacy and safety.
hutchmed (china) (00013) rose 3.24% during the Hong Kong Stock Connect program. Huayuan Securities indicated that the company has a rich pipeline of innovative products and maintains a "buy" rating.
King Wescend News | The stock price of Hutchmed (China) (0013) fluctuated upward, and as of press time, it rose by 3.24%, to HKD 30.25, with a turnover of HKD 79.8885 million. Huayuan Securities issued a research report stating that the company's innovative product pipeline is rich, global progress is smooth, maintaining a "buy" rating for the company. The company expects the comprehensive revenue of tumor/immune business in 2024 to be USD 0.3 billion to USD 0.4 billion (benefiting from the target growth of sales of listed tumor products and the franchise fee increase of 30%-50%). In addition, as of the end of 2023, the company had cash on hand of USD 0.886 billion. The bank predicts 2024.
U.S. stock abnormality | Northeast securities maintains a "buy" rating, and hutchmed (china) (HCM.US) rose more than 8%.
As of press time, the stock has risen over 8% to $19.245.
Brokerage Focus: Northeast Securities maintains a 'buy' rating on Hutchmed (China) (00013), expecting the global expansion of the company's products to continue to catalyze the fundamental value of the company.
Jingu Finance | Northeast Securities issued a research report, stating that Hutchmed (China) held a conference in Shanghai to share its latest R&D progress and live stream it through the network. The senior management team of the company shared their R&D strategy and vision at the conference, as well as some projects in the company's rich and innovative candidate drug pipeline, including the latest progress of products such as savolitinib, sulfatinib, and HMPL-306. The bank continued to point out that the company's recent R&D progress has been rapid, with multiple products making simultaneous efforts, demonstrating excellent clinical data and competitive landscape, and continuously promoting global product development, which is expected to continue to catalyze the company's fundamental value growth.
HK stocks fluctuation: Hutchmed (China) (00013) rises by more than 9% again, the company recently shared the latest pipeline progress, institutions stated that there are multiple catalysts in the second half of the year.
Hutchmed (China) (00013) rose more than 9%, as of press time, it rose 7.03% to HKD 29.7, with a turnover of HKD 0.114 billion.
No Data
DailyHunt : Do you think is ready?
Momentum TraderOP DailyHunt: Already Bo from pivot. Don’t chase high!